Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 3/20 | 0.31 |
| ▸ | CDK8 | P49336 | 3/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.31 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9780105 | 0.71 | TSHR (0.40) | KDM4EGAAMAOB | |
| SCHEMBL18572463 | 0.70 | ALDH1A1 (0.45) | KDM4EGAAMAOBCCNCCDK8 | |
| SCHEMBL14661529 | 0.69 | — | — | |
| SCHEMBL3227929 | 0.68 | KDM4E (0.47) | KDM4EGAAMAOB | |
| SCHEMBL7015598 | 0.63 | CDC25B (0.36) | — | |
| SCHEMBL4822863 | 0.63 | MAOB (0.39) | MAOB | |
| Hydrochloric Acid SCHEMBL3597821 | 0.61 | MAOB (0.38) | MAOB | |
| SCHEMBL16357239 | 0.61 | MAPT (0.42) | KDM4EMAOB | |
| SCHEMBL16836537 | 0.61 | KDM4E (0.39) | KDM4EMAOB | |
| SCHEMBL12273329 | 0.60 | MAOB (0.35) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9221832-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2734526-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013014587-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | KDM4E 2890/4885GAA 3922/4885MAOB 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.